Fairmont Chateau Lake Louise Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Therapeutic Modulation of RNA Using Oligonucleotides (B7)


Organizer(s) C. Frank Bennett and Thomas Tuschl
February 8—13, 2009
Fairmont Chateau Lake Louise • Lake Louise, AB Canada
Abstract Deadline: Oct 9, 2008
Late Abstract Deadline: Nov 6, 2008
Scholarship Deadline: Oct 9, 2008
Early Registration Deadline: Dec 8, 2008

Sponsored by Alnylam Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Santaris Pharma A/S

Summary of Meeting:
The recent discoveries of the RNAi pathway in mammalian cells and the finding that oligonucleotides can activate the innate immune system through Toll-like receptors have resulted in increased interest in oligonucleotide-based therapeutics. There are two basic therapeutic approaches in which oligonucleotides are being utilized: (1) binding to RNA resulting in selective inhibition of gene expression; and (2) modulating protein function by direct binding to proteins. Although both approaches share common manufacturing, toxicology and ADME issues, oligonucleotides that are designed to bind RNA inside the cell have a fundamental different set of challenges than oligonucleotides designed to bind to proteins outside the cell. This meeting will focus on the former application. A goal of this meeting is to bring together scientists from both the basic science disciplines and applied disciplines to gain a common understanding of the attributes and challenges the technology faces. This meeting will consider basic mechanisms by which oligonucleotides can be exploited to modulate gene expression, mechanisms for distribution of oligonucleotides to tissues and within cells and how chemistry and/or formulations can improve the pharmaceutical properties of oligonucleotides. Finally recent advances in both preclinical applications and clinical results will be presented.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 8

15:00—19:30
Registration

Alpine Gallery
18:30—19:30
Refreshments

Heritage Hall
19:30—19:45
Opening Remarks

Mount Temple A-B
* C. Frank Bennett, Ionis Pharmaceuticals, Inc., USA

* Thomas Tuschl, HHMI/Rockefeller University, USA

19:45—21:45
Keynote Session
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
Thomas R. Gingeras, Cold Spring Harbor Laboratory, USA
The RNA World

Stanley T. Crooke, Ionis Pharmaceuticals, Inc., USA
Antisense Technology: Past, Present, and Future


MONDAY, FEBRUARY 9

07:00—08:00
Breakfast

Tom Wilson Restaurant
08:00—11:00
Natural RNA Regulatory Pathways
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
Jack D. Keene, Duke University Medical Center, USA
Post-Transcriptional Coordination of Gene Expression

* Thomas Tuschl, HHMI/Rockefeller University, USA
Small RNA Sequencing Resolves Posttranscriptional Regulatory Networks

Dinshaw J. Patel, Memorial Sloan Kettering Cancer Center, USA
Structural Biology of Argonaute-Mediated RNA Silencing

Laura Ranum, University of Florida, USA
Double the Trouble: Bidirectional Expression of the SCA8 CAG/CTG Expansion Mutation - Evidence for RNA and Protein Gain of Function Effects

09:20—09:40
Coffee Break

Heritage Hall
11:00—13:00
Poster Setup

Mount Temple C
13:00—22:00
Poster Viewing

Mount Temple C
16:30—17:00
Coffee Available

Heritage Hall
17:00—19:15
Medicinal Chemistry of Oligonucleotides
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
Steven A. Benner, Foundation for Applied Molecular Evolution, USA
Synthetic Biology for Human Diagnostics Applications

Jesper Wengel, University of Southern Denmark, Denmark
LNA (Locked Nucleic Acid) and UNA (Unlocked Nucleic Acid)

* Muthiah Manoharan, Alnylam Pharmaceuticals, Inc., USA
Medicinal Chemistry of siRNAs

Eric E. Swayze, Ionis Pharmaceuticals, Inc., USA
Short Talk: Conformational Constraint of Oligonucleotides with Non-Bicyclic Nucleosides: Hexitol Nucleoside Containing Antisense Oligonucleotides Improve Potency in Animals.

19:15—20:15
Social Hour with Lite Bites

Mount Temple C
19:30—22:00
Poster Session 1

Mount Temple C

TUESDAY, FEBRUARY 10

07:00—08:00
Breakfast

Tom Wilson Restaurant
08:00—11:00
Mechanisms of Biodistribution of Oligonucleotides
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
Steven F. Dowdy, University of California, San Diego, USA
Peptide Transduction Domain Delivery of siRNA Macromolecules

* C. Frank Bennett, Ionis Pharmaceuticals, Inc., USA
Mechanisms of Oligonucleotide Distribution To Cells

Markus Stoffel, ETH Zürich, Switzerland
Mechanisms of Lipophile Oligonucleotide Biodistribution

HaiFang Yin, Oxford University, UK
Short Talk: A Tissue-Specific Targeting Peptide Domain Directs Enhanced Systemic Antisense Oligonucleotide-Induced Splice Correction of the DMD Gene and Functional Restoration in Dystrophin-Deficient mdx Mice

09:20—09:40
Coffee Break

Heritage Hall
11:00—12:00
Lunch

Tom Wilson Restaurant
12:00—14:00
Workshop: Issues with Target Validation Using Oligonucleotides

Mount Temple A-B
* Victor Kotelianski, Promedior, USA

Devin Leake, Gen9, Inc., USA
Design and Optimization of siRNA Oligonucleotides

Steffen Panzner, Novosom AG, Germany
Approaches in the Systemic Delivery Oligonucleotides: Chemistries, Mechanisms and in vivo Applications

Xiao-Dong Yang, Intradigm Corporation, UK
RNAi Nanoplex Technology for Systematic Delivery of siRNA

Susan M. Freier, Ionis Pharmaceuticals, Inc., USA
Identification of Antisense Oligonucleotides for Target Validation Using In Silico and In Vitro Methods

Xavier J. de Mollerat du Jeu, Life Techonologies, USA
Invivofectamine™-New Delivery Reagent for in vivo Delivery of Stealth™RNAi

14:00—14:30
Coffee Available

Heritage Hall
14:30—16:30
Intersection of RNAi/miRNA Silencing with other Cellular Pathways (Innate Immunity, Editing, Intercellular Traffic of RNA, Viruses)
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
Gunther Hartmann, Universitätsklinikum Bonn, Germany
Oligonucleotide Interaction with Innate Immune Receptors

Aimee Jackson, miRagen Therapeutics, USA
microRNA Therapeutics: Opportunities and Challenges

* Mark A. Kay, Stanford University, USA
Pharmacological Effects of siRNA/shRNA Expression on RISC Pathway

Ivone Guzman Bruno, Baylor College of Medicine, USA
Short Talk: A Brain-Enriched miRNA Regulates mRNA Surveillance Pathways


WEDNESDAY, FEBRUARY 11

07:00—08:00
Breakfast

Tom Wilson Restaurant
08:00—11:00
Target Validation
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
* Stephen W. Fesik, Vanderbilt University School of Medicine, USA
Identification and Validation of Oncology Targets using RNAi

Siew Peng Ho, Bristol-Myers Squibb Company, USA
Oligonucleotide based Approaches for in Vivo Validation of Drug Targets

John Cryan, University College Cork, Ireland
Validating Neuronal Targets

Varman T. Samuel, Yale University, USA
Short Talk: Validating Novel Metabolic Targets with Antisense Oligonucleotides: Surprises and Insights

09:20—09:40
Coffee Break

Heritage Hall
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Mount Temple C
13:00—22:00
Poster Viewing

Mount Temple C
16:30—17:00
Coffee Available

Heritage Hall
17:00—19:00
Nucleic Acids Formulations
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
Alan Sachs, Thermo Fisher Scientific, USA
Small Interfering RNA as a Therapeutic Modality

* Daniel G. Anderson, Massachusetts Institute of Technology, USA
Combinatorial Development of Synthetic siRNA Delivery Systems

Masahiko Kuroda, Tokyo Medical University, Japan
Short Talk: Therapeutic Silencing of an Endogenous Gene by the siRNA Cream in an Arthritis Model Mouse

19:00—20:00
Social Hour with Lite Bites

Mount Temple C
19:30—22:00
Poster Session 2

Mount Temple C

THURSDAY, FEBRUARY 12

07:00—08:00
Breakfast

Tom Wilson Restaurant
08:00—11:00
Non-Traditional RNA Targets as Therapeutic Opportunities
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
* Ryszard Kole, Ercole Biotech Consulting, USA
Splice Switching Oligonucleotides as Potential Therapeutics

Christine Esau, Arcturus Therapeutics, USA
Therapeutic Targeting of MicroRNAs

Chang-Zheng Chen, Stanford University, USA
Micromanaging the Immune System by microRNA Genes

Noga Yerushalmi, Rosetta Genomics, Israel
The Use of Antisense Oligonucleotides Against miRNA as a Potential Therapy for Hepatocellular Carcinoma

Eva van Rooij, Hubrecht Institute, Netherlands
Short Talk: The Myriad Roles of MicroRNAs in Heart Disease

09:20—09:40
Coffee Break

Heritage Hall
11:00
On Own for Lunch

16:30—17:00
Coffee Available

Heritage Hall
17:00—19:15
Clinical Trials
Meeting has ended...abstracts no longer viewable online.

Mount Temple A-B
* John A. Schmidt, National Institutes of Health, USA
Clinical Development Introduction

Akshay Vaishnaw, Alnylam Pharmaceuticals Inc., USA
A Phase II Trial of ALN-RSV01, an RNAi Therapeutic for Respiratory Syncytial Virus

Nuket Desem, Spinifex Pharmaceuticals Pty Ltd, Australia
ATL1102, an Antisense Drug Targeting VLA-4, Significantly Reduces the Development of Active Lesions in Relapsing-Remitting Multiple Sclerosis

Sancy Ann Leachman, Oregon Health & Science University, USA
Short Talk: First-in-Skin siRNA Clinical Trial

Annemieke Aartsma-Rus, Leiden University Medical Center, Netherlands
Short Talk: Clinical Trials for Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy

19:15—20:15
Social Hour with Lite Bites

Victoria Room
20:00—23:00
Entertainment

Victoria Room

FRIDAY, FEBRUARY 13

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge additional support for this conference from:

Alnylam Pharmaceuticals, Inc. ChemGenes Corporation
Integrated DNA Technologies Isis Pharmaceuticals, Inc.
Santaris Pharma A/S
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Alnylam Pharmaceuticals, Inc.


Bristol-Myers Squibb Company


Isis Pharmaceuticals, Inc.


Merck & Co, Inc. /Sirna Therapeutics


novosom AG


Regulus Therapeutics Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Cell Press Royal Society of Chemistry

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676